Methicillin-resistant Staphylococcus aureus (MRSA) infections are potentially deadly, affecting millions of Americans every year. A new technology developed jointly by NAU and the University of Maryland, Baltimore was licensed to Serenta Biotechnology, LLC, a start-up company based in Gaithersburg, Maryland. The license is the basis for a multivalent vaccine against infections caused by Staphylococcus aureus.